

#12
Gef/16 + Font
2-21-02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Barbara K. Finck et al.

Docket No.: 2945-A

Group Art Unit: 1647

Serial No: 09/602,351

Examiner: D. Romeo

Filed: June 23, 2000

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR
TREATMENT OF MEDICAL DISORDERS

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX NON-FEE

Assistant Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

FEB 19 2002

RECEIVED

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449, and copies are attached hereto. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 C.F.R. 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, applicants authorize the Commissioner to charge applicants' deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,

Diana K. Sheiness

Diana K. Sheiness
Registration No. 35,356
DIRECT DIAL (206) 470-4818

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON-FEE, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: January 18, 2002

Signed: D. F. Lindholm
D. F. Lindholm